Celltrion Healthcare wins three awards including ‘Company of the Year’ at the Global Pharmaceutical and Bio Awards… Most awards

Celltrion Healthcare was awarded to companies leading the development of the global pharmaceutical bio industry at the ‘Global Generics & Biosimilars Awards 2021 (GGBA)’ held in Milan, Italy on the 10th (local time). It was announced on the 11th that it won three awards including ‘Company of the Year’.

GGBA is an event that selects and awards companies that have achieved achievements in the global market during the year for detailed items such as pharmaceutical and biotechnology companies’ management performance, innovation activities, social contribution, and compliance with laws. It is hosted by ‘Informa Pharma Intelligence’, a global biopharma data company. The judges will be judged by a panel of 15 judges made up of global experts who are recognized for their authority in the field of pharmaceutical biotechnology. Winners in each field are selected through a rigorous and fair screening process.

In the case of Celltrion Healthcare, it won 3 gold medals at the 8th GGBA this year. It won three categories: Company of the Year, Biosimilar Initiative of the Year, and Value Added Medicine Initiative of the Year. In this award, which was awarded in a total of 14 categories, Celltrion Healthcare was recorded as the company that won the most categories, beating Sandoz, who won two categories, and others.

This year’s company is a field that selects leading companies that have achieved outstanding performance in the global pharmaceutical and bio industry throughout the year and have led the industrial development. This year’s Biosimilar Initiative selects and awards companies that have played a leading role in expanding the global prescription of biosimilars. In this year’s IMD initiative, Celltrion Healthcare was recognized for its contribution to providing new treatment options to patients by launching ‘Remsima SC’, the world’s first infliximab SC formulation. Starting with Remsima, the world’s first antibody biosimilar in 2013, it has led the growth of the global bio industry for over 9 years, proving its contribution to improving access to medical care for patients around the world.

A Celltrion Healthcare official said, “Through this award, we will do our best to fulfill our responsibility and vocation as a global leading bio company while once again reminding ourselves of the role of the pharmaceutical bio industry to deliver new hope to patients suffering from diseases. I will do my best,” he said.

Reporter Min-beom Kim, Donga.com [email protected]

Source: 동아닷컴 : 동아일보 전체 뉴스 by www.donga.com.

*The article has been translated based on the content of 동아닷컴 : 동아일보 전체 뉴스 by www.donga.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!